Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Dosing, risks, monitoring, and evidence for antipsychotics, mood stabilizers, and adjunctive agents — built for clinicians, students, and educators.
150
Medications covered
5
Condition hubs
117
Glossary terms
Monthly
Review cadence
Tools and references for evidence-based psychiatric medication management.
Review oral and LAI options with label links, monitoring checklists, and printable summaries.
Line up to four medications to contrast dosing ranges, risks, monitoring, and label freshness.
Checklists and shortcuts for antipsychotics, mood stabilizers, LAIs, and safety monitoring.
Look up abbreviations and pharmacology terms referenced across medication pages.
Filter clinical trials, cohort studies, and guidelines by drug, year, and open-access availability.
New drug profiles, content refreshes, and structured data improvements as they roll out.
Added a new Real-world experience section to Cobenfy covering early clinical observations, patient-reported themes, and clinician notes for this first-in-class muscarinic antipsychotic. This establishes a reusable content pattern for newly FDA-approved drugs.
Cobenfy profileAdded milsaperidone (Bysanti), a second-generation antipsychotic approved Feb 2026 for schizophrenia and acute manic/mixed episodes in bipolar I disorder. Includes full drug profile, evidence entries, and compare-table integration.
MilsaperidoneAdded GLP-1 metabolic meds (Ozempic/Wegovy/Mounjaro/Zepbound) + evidence + glossary terms
Explore antipsychotics, mood stabilizers, and adjunctive agents with labeling and monitoring context.
Dive into condition-specific hubs with curated medication guidance, treatment algorithms, and clinical FAQs.
Antipsychotic therapy, LAI options, and monitoring.
Open hubMood stabilizers, atypical antipsychotics, and combination strategies.
Open hubAntidepressant classes, augmentation, and treatment-resistant pathways.
Open hubFirst-line agents, benzodiazepine considerations, and non-pharmacologic adjuncts.
Open hubSedative-hypnotics, off-label options, and sleep hygiene integration.
Open hubCommon questions about PsychMed and how to use it.